Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Change in Receivables (2016 - 2017)

Armata Pharmaceuticals (ARMP) has disclosed Change in Receivables for 5 consecutive years, with -$2000.0 as the latest value for Q2 2017.

  • Quarterly Change in Receivables fell 150.0% to -$2000.0 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was -$11000.0 through Sep 2017, up 31.25% year-over-year, with the annual reading at $467000.0 for FY2020, N/A changed from the prior year.
  • Change in Receivables hit -$2000.0 in Q2 2017 for Armata Pharmaceuticals, up from -$10000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $129000.0 in Q2 2013 to a low of -$140000.0 in Q4 2013.
  • Historically, Change in Receivables has averaged -$588.24 across 5 years, with a median of $4000.0 in 2014.
  • Biggest five-year swings in Change in Receivables: soared 152.14% in 2014 and later tumbled 2600.0% in 2015.
  • Year by year, Change in Receivables stood at -$140000.0 in 2013, then skyrocketed by 152.14% to $73000.0 in 2014, then rose by 16.44% to $85000.0 in 2015, then crashed by 98.82% to $1000.0 in 2016, then tumbled by 300.0% to -$2000.0 in 2017.
  • Business Quant data shows Change in Receivables for ARMP at -$2000.0 in Q2 2017, -$10000.0 in Q1 2017, and $1000.0 in Q4 2016.